
Profound Medical Corp
TSX:PRN

Net Margin
Profound Medical Corp
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
CA |
![]() |
Profound Medical Corp
TSX:PRN
|
199.3m CAD |
-269%
|
|
US |
![]() |
Abbott Laboratories
NYSE:ABT
|
233.4B USD |
32%
|
|
US |
![]() |
Intuitive Surgical Inc
NASDAQ:ISRG
|
200.7B USD |
28%
|
|
US |
![]() |
Boston Scientific Corp
NYSE:BSX
|
156.9B USD |
12%
|
|
US |
![]() |
Stryker Corp
NYSE:SYK
|
150.6B USD |
12%
|
|
IE |
![]() |
Medtronic PLC
NYSE:MDT
|
110.9B USD |
13%
|
|
DE |
![]() |
Siemens Healthineers AG
XETRA:SHL
|
54.9B EUR |
9%
|
|
US |
![]() |
Becton Dickinson and Co
NYSE:BDX
|
50.3B USD |
7%
|
|
US |
![]() |
Edwards Lifesciences Corp
NYSE:EW
|
45.9B USD |
75%
|
|
US |
![]() |
IDEXX Laboratories Inc
NASDAQ:IDXX
|
41.8B USD |
23%
|
|
CN |
![]() |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
274.2B CNY |
31%
|
Profound Medical Corp
Glance View
Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Profound Medical Corp's most recent financial statements, the company has Net Margin of -269.4%.